DOI: 10.1111/1759-7714.15197

CASE REPORT

Difficulty differentiating primary mediastinal classical Hodgkin lymphoma from inflammatory myofibroblastic tumor: A case report

Kentaro Akata ^{1,2} 💿	Kei Yamasaki ² 🖻	Yosuke Chiba ²	Takako Kawaguchi ²
Hiroki Dosaka ²	Toshiki Morimoto ³	Yasuyuki Higashi ³	Chinatsu Nishida ³
Shohei Shimajiri ⁴	Kazuhiro Yatera ²		

¹Division of Infection Control and Prevention, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan

²Department of Respiratory Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan

³Department of Environmental Health Engineering, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan

⁴Department of Pathology, University of Environmental and Occupational Health, Japan, Kitakyushu, Japan

Correspondence

Kentaro Akata, Division of Infection Control and Prevention, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishiku, Kitakyushu city, Fukuoka, 807-8555, Japan. Email: kentarouakata@med.uoeh-u.ac.jp

Abstract

A 20-year-old Japanese man visited our hospital because an enlarged mediastinal shadow had been detected on chest x-ray. Chest computed tomography revealed a large mediastinal mass with multiple lymph node enlargement, pericardial effusion, and bilateral pleural effusion. He was diagnosed with inflammatory myo-fibroblastic tumor (IMT) based on a thoracoscopic tumor biopsy. Initial cortico-steroid and celecoxib treatment was only partially effective; therefore, additional tumor rebiopsy and left axillary lymph node biopsy were performed. Based on the findings, the patient was rediagnosed with classical Hodgkin lymphoma (CHL). To date, there has only been one report of a case initially diagnosed as IMT and rediagnosed as CHL, as in our case, and only three reports of malignant lymphoma mimicking IMT. When IMT is suspected based on pathological findings and subsequently with treatment failure, possible CHL and performing rebiopsy should be considered.

K E Y W O R D S

Hodgkin lymphoma, inflammatory myofibroblastic tumor, malignant lymphoma

INTRODUCTION

Classical Hodgkin lymphoma (CHL) is a rare lymphatic system malignancy.¹ Malignant lymphoma (ML), including CHL, accounts for approximately 20% of mediastinal tumors.^{2,3} Inflammatory myofibroblastic tumor (IMT) is characterized by myofibroblastic spindle cells along with inflammatory cell infiltration.⁴ Given that CHL induces pronounced inflammatory alterations in tumor and surrounding tissues,⁵ leading to fibrosis as seen in IMT,^{6–12} accurate CHL diagnosis may be difficult because of extensive fibrotic areas in CHL.¹³ To date, there has been only one case report of CHL mimicking IMT¹⁴ and only three reports of ML mimicking IMT.^{15,16} Here, we present a rare case initially diagnosed as IMT and rediagnosed as CHL on second biopsy.

CASE REPORT

A 20-year-old healthy Japanese man with a history of childhood asthma presented with a dry cough. One month later, he developed dyspnea and night sweats and was treated for asthma, but his symptoms did not improve. Two months later, an enlarged mediastinal shadow was detected on a chest x-ray, and he was subsequently transferred to our hospital. The patient exhibited marked edema from the face to the neck and on both upper extremities, with jugular vein distention. Chest auscultation revealed coarse crackles in both lung fields. Laboratory findings on admission (Table 1) revealed elevated serum C-reactive protein (CRP; 7.11 mg/ dL) and soluble interleukin-2 receptor (1563 U/mL) levels. A chest x-ray film (Figure 1a1) revealed an enlarged mediastinal shadow, and chest computed tomography

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

^{© 2023} The Authors. *Thoracic Cancer* published by John Wiley & Sons Australia, Ltd.

TABLE 1 Laboratory findings on admission.

Hematology		Serology	
WBC	9,400/µL	hCG	1.2 mIU/mL
Neu	78.8%	AFP	0.7 ng/mL
Lym	4.5%	CEA	1.4 ng/dL
Mon	13.4%	CYFRA	0.5 ng/dL
Eos	0%	ProGRP	35 pg/dL
Bas	0.1%	IgG	789 mg/dL
RBC	$573 \times 10^4/\mu L$	sIL-2R	1563 U/mL
Hb	16.0 g/dL	EB VCA-IgM	<10
Hct	48.4%	EB VCA-IgG	<10
Plt	$28.2 \times 10^4/\mu L$	EBNA	<10
Biochemistry		Blood gas analysis (O2 3L/min, nasal)	
ТР	5.6 g/dL	pH	7.42
Alb	2.7 g/dL	PaO ₂	111 Torr
T-Bil	0.4 mg/dl	PaCO ₂	38 Torr
AST	13 IU/L	HCO ₃ ⁻	24.6 mmol/L
ALT	12 IU/L	BE	0.4 mmol/L
ALP	184 IU/L		
γ-GTP	21 IU/L		
LDH	184 IU/L		
BUN	9 mg/dL		
Cr	0.67 mg/dL		
Na	136 mEq/L		
К	4.3 mEq/L		
Cl	101 mEq/L		
CRP	7.11 mg/dl		

Abbreviations: AFP, alpha fetoprotein; Alb, albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BE, base excessBUN, blood urea nitrogen; CEA, carcinoembryonic antigen; Cre, creatinine; CRP, C-reactive protein; hCG, human chorionic gonadotropin; CYFRA, cytokeratin 19 fragment; EBNA, Epstein–Barr virus-nuclear antigen antibody; EB VCA, Epstein–Barr virus viral-capsid antigen; Hb, hemoglobin; HCO₃⁻⁻, hydrogencarbonate; Ht, hematocrit; IgG, immunoglobulin G; LDH, lactate dehydrogenase; Pro GRP, progastrin-releasing peptide; PaO₂, partial pressure of oxygen in arterial blood; PaCO₂, partial pressure of carbon dioxide in arterial blood; pH, power of hydrogen; PLT, platelet; RBC, red blood cell; sIL-2R, soluble interleukin 2 receptor; T-Bil, total bilirubin; TP, total protein; γ-GTP, gamma-glutamyl transferase; WBC, white blood cell.

(CT) (Figure 1a2,a3) showed a 15×10 -cm mass from the anterior mediastinum to the middle mediastinum, with bilateral supraclavicular lymph node enlargement, #7 and #12R mediastinal lymph nodes, and left axillary lymph node, as well as pericardial and bilateral pleural effusions. Thoracoscopic anterior mediastinal tumor biopsy was performed under local anesthesia, and histopathological examination revealed proliferation of spindle-shaped cells negative for anaplastic lymphoma kinase (ALK) but positive for α -smooth muscle actin, and inflammatory cell infiltration (Figure 2a1,a2). Based on these pathological findings, he was diagnosed with IMT. Surgical removal of the tumor was difficult because it surrounded blood vessels. Therefore, corticosteroid and celecoxib therapy was started and was initially effective (Figure 1b), but the tumor continued to grow (Figure 1c). Secondary thoracoscopic mediastinal tumor biopsy and left axillary lymph node biopsy were performed, and histopathological examination revealed the presence of Hodgkin and Reed/Sternberg (HRS) cells positive for CD30

and CD15 amidst a background of spindle cells (Figure 2b1-b4), diagnostic for stage IV nodular sclerosing CHL (Ann Arbor classification). On the 112th day, the patient was transferred to the hematology department to receive systemic chemotherapy, and his tumor shrunk after three years of chemoradiotherapy (Figure 1d1-d4). He is currently alive, seven years after autologous stem cell transplantation completion.

DISCUSSION

Our patient represents a rare case of rediagnosis of CHL after initial IMT diagnosis. HL occasionally mimics IMT⁶⁻¹² because of pronounced inflammatory alterations in tumor and surrounding tissues⁵ that leads to fibrosis as observed in our patient, and an accurate diagnosis of CHL may sometimes be difficult because of extensive fibrotic areas in the pathological lesions. When the pathological



FIGURE 1 (a) Chest x-ray film (a1) and computed tomography (CT) images (a2 and a3) on admission, showing a large mediastinal mass with pericardial and bilateral pleural effusions and left axillary lymphadenopathy (red arrow). (b) Chest x-ray (b1) and CT images (b2 and b3) seven days after the start of corticosteroid treatment, showing shrinkage of the mediastinal tumor and lymph nodes (red arrow). (c) Chest x-ray film (c1) and CT images (c2 and c3) two months after the start of corticosteroid treatment, showing regrowth of the mediastinal tumor and lymph nodes (red arrow). (d) Chest x-ray film (d1) and CT images (d2 and d3) three years after the start of treatment for CHL, showing mediastinal tumor shrinkage and lymph node enlargement disappearance. CHL, classical Hodgkin lymphoma.

findings suggest IMT and IMT treatment is ineffective, it is important to consider the possibility of ML and perform additive biopsy to elucidate proper pathological diagnosis.

In the pathological lesions of patients with CHL, HRS cells are surrounded by reactive cells such as lymphocytes, macrophages, eosinophils, mast cells, plasma cells, stromal cells, fibroblasts, and other cell types. Therefore, it may occasionally be difficult to differentiate CHL from IMT, when stromal cells and fibroblasts, which are instigated by interleukin-13, tumor necrosis factor-alpha, transforming growth factor-beta, and other mediators secreted by HRS cells,⁵ are abundantly present. To date, only three cases of ML mimicking IMT have been reported (Table 2).^{14–16} In Case 2, a buccal mucosa mass was excised, leading to the diagnosis of IMT.¹⁶ Cases 1 and 3 were initially diagnosed with IMT based on initial biopsy results, as in our case. Their tumors proliferated despite treatment for IMT, and second biopsies revealed ML. In Case 1, the tumor completely vanished after IMT treatment, suggesting that the tumor emerged after IMT treatment discontinuation.¹⁵

In contrast, our patient presented CHL mimicking IMT from the onset because of the relatively rare presentation of multiple lesions and lymphadenopathy.

Among the histological CHL subtypes, nodular sclerosis CHL predominates in primary mediastinal lesions. Most patients experience constitutional symptoms (B symptoms) including fevers, night sweats, and weight loss.¹⁷ Our patient exhibited a mediastinal mass accompanied by multiple lymph node enlargement along with B symptoms. Pathological findings of CHL encompass atypical cells positive for CD15 and CD30, referred to as HRS cells, which are diagnostic hallmarks of CHL. Anaplastic large cell lymphoma cells resemble HRS cells and are positive for ALK and CD30.¹⁸ In our patient, the diagnosis of CHL was based on tumor cells being positive for CD15, but negative for ALK.

In conclusion, our patient was initially diagnosed with IMT, which was rediagnosed as CHL. In patients with IMT with unfavorable treatment response, it is important to consider possible ML and perform additive biopsy for proper diagnosis.

412 WILEY-



FIGURE 2 Histological findings on first biopsy (a1), showing that the tumor is composed of spindle cells arranged in a storiform pattern, with variable inflammatory cells mainly composed of lymphocytes (hematoxylin–eosin stain, high-power field). Immunohistochemical staining of α -SMA (a2), showing that the spindle cells were positively stained (high-power field). Histological findings on second biopsy (b1), showing that the tumor is composed of HRS cells, including Hodgkin (arrow head) and Reed-Sternberg (arrow) cells, surrounded by spindle cells in a storiform pattern with inflammatory cells mainly composed of lymphocytes (hematoxylin–eosin stain, high-power field). Immunohistochemical staining of α -SMA (b2), showing that the spindle cells were positively stained (high-power field). Immunohistochemical staining of CD30 and CD15 (b3, b4), showing that HRS cells (arrow) were positively stained (high-power field). α -SMA, α -smooth muscle actin; He, hematoxylin–eosin; HRS, Hodgkin and Reed/Sternberg.

TABLE 2 Reported cases of malignant ly	ymphoma mimicking	g inflammatory m	nyofibroblastic tumor
--	-------------------	------------------	-----------------------

Case	Age (years)/sex	Type of lymphoma	Lesion site	Diagnosis on first biopsy	Diagnosis on second biopsy	References	Year of reporting
1	42/F	B cell lineage (unknown details)	Brain	IMT	B cell lineage	15	1996
2	78/F	Marginal zone B-cell lymphoma	Buccal mucosa	Marginal zone B-cell lymphoma	-	16	2008
3	37/M	Hodgkin lymphoma	Mediastinum	IMT	Hodgkin lymphoma	14	2019
Present case	20/M	Hodgkin lymphoma	Mediastinum	IMT	Hodgkin lymphoma		

Abbreviations: IMT, inflammatory myofibroblastic tumor; MZBL, marginal zone B cell lymphoma.

AUTHOR CONTRIBUTIONS

KA wrote the manuscript draft. K. Yamasaki, YC, TK, HD, TM, YH, CN, SS, and K. Yatera critically revised the manuscript draft. All authors read and approved the final manuscript.

ACKNOWLEDGMENTS

None.

CONFLICT OF INTEREST STATEMENT

The author report no conflict of interest.

ORCID

Kentaro Akata https://orcid.org/0000-0001-5587-1899 Kei Yamasaki https://orcid.org/0000-0003-1876-3287

REFERENCES

- Cartwright R, Brincker H, Carli PM, Clayden D, Coebergh JW, Jack A, et al. The rise in incidence of lymphomas in Europe 1985-1992. Eur J Cancer. 1999;35:627–33.
- 2. Whooley BP, Urschel JD, Antkowiak JG, Takita H. Primary tumors of the mediastinum. J Surg Oncol. 1999;70:95–9.
- Bacha EA, Chapelier AR, Macchiarini P, Fadel E, Dartevelle PG. Surgery for invasive primary mediastinal tumors. Ann Thorac Surg. 1998; 66:234–9.
- Coffin CMFJ. Inflammatory myofibroblastic tumour. WHO Pathology & Genetics of Tumours of Soft Tissue and Bone. Lyon: IARC Press; 2002.
- Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol. 2011;29:1812–26.
- 6. Özbalak M, Torun ES, Özdemirli M, Uçar AR, Akpınar TS, Taşçıoğlu C, et al. Inflammatory myofibroblastic tumor mimicking a relapse in a patient with Hodgkin's lymphoma: report of an unusual case and review of the literature. Clin Case Rep. 2017;5:945–9.

414 WILEY-

- Howman-Giles R, London K, McCowage G, Graf N, Harvey J. Pulmonary inflammatory myofibroblastic tumor after Hodgkin's lymphoma and application of PET imaging. Pediatr Surg Int. 2008;24:947–51.
- Sanders BM, West KW, Gingalewski C, Engum S, Davis M, Grosfeld JL. Inflammatory pseudotumor of the alimentary tract: clinical and surgical experience. J Pediatr Surg. 2001;36:169–73.
- Gasljević G, Lamovec J. Malignant lymphoma of the stomach in association with inflammatory myofibroblastic tumor of the spleen. A Case Report. Pathol Res Pract. 2003;199:745–9.
- Cotelingam JD, Jaffe ES. Inflammatory pseudotumor of the spleen. Am J Surg Pathol. 1984;8:375–80.
- Ilic V, Dunet V, Beck-Popovic M, Boubaker A. Pulmonary inflammatory myofibroblastic tumour after Hodgkin's lymphoma. BMJ Case Rep. 2014;2014:bcr2013202491. https://doi.org/10.1136/bcr-2013-202491
- 12. Kroft SH, Stryker SJ, Winter JN, Ergun G, Rao MS. Inflammatory pseudotumor of the pancreas. Int J Pancreatol. 1995;18:277–83.
- Singh HK, Silverman JF, Powers CN, Geisinger KR, Frable WJ. Diagnostic pitfalls in fine-needle aspiration biopsy of the mediastinum. Diagn Cytopathol. 1997;17:121–6.
- Sandoval L, França MV, Sanmartino D, Zattar PF. ALK negative inflammatory myofibroblastic tumor synchronous with classical Hodgkin lymphoma. Case Rep Oncol. 2019;12:119–25.

- Hudson HL, Hinton DR, Friedman DI, Apuzzo M, Chandrasoma P, Garbut M, et al. Pseudotumor associated with CNS lymphoma. J Neuroophthalmol. 1996;16:208–11.
- Kojima M, Hirabayashi K, Yokoyama J, Uesawa M, Tsunoda S, Igarashi S. Marginal zone B-cell lymphoma arising from buccal mucosa resembling inflammatory myofibroblastic tumor of the soft tissue. Head Neck Pathol. 2008;2:218–21.
- 17. Duwe BV, Sterman DH, Musani AI. Tumors of the mediastinum. Chest. 2005;128:2893–909.
- Montes-Mojarro IA, Steinhilber J, Bonzheim I, Quintanilla-Martinez L, Fend F. The pathological spectrum of systemic anaplastic large cell lymphoma (ALCL). Cancers (Basel). 2018;10:10.

How to cite this article: Akata K, Yamasaki K, Chiba Y, Kawaguchi T, Dosaka H, Morimoto T, et al. Difficulty differentiating primary mediastinal classical Hodgkin lymphoma from inflammatory myofibroblastic tumor: A case report. Thorac Cancer. 2024;15(5):410–4. <u>https://doi.org/10.1111/1759-7714.</u> 15197